Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04872790
Title Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
OHSU Knight Cancer Institute RECRUITING Portland Oregon 97239 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field